nach oben

Current Oncology Reports

Erschienen in:

01.06.2013 | Hot Topic

The Role of Vascular Endothelial Growth Factor in the Pathogenesis, Diagnosis and Treatment of Malignant Pleural Effusion

verfasst von: Michael Bradshaw, Aaron Mansfield, Tobias Peikert

Erschienen in: Current Oncology Reports | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Malignant pleural effusions (MPEs) are a significant source of cancer-related morbidity. Over 150,000 patients in the United States suffer from breathlessness and diminished quality of life due to MPE each year. Current management strategies are of mostly palliative value and focus on symptom control; they do not address the pathobiology of the effusion, nor do they improve survival. Further elucidation of the pathophysiological mechanisms, coupled with the development of novel treatments such as intrapleural chemotherapeutics targeting this process, has the potential to greatly improve the efficacy of our current management options. Vascular endothelial growth factor-A (VEGF-A) has been implicated as a critical cytokine in the formation of malignant pleural effusions. Elevated levels of VEGF produced by tumor cells, mesothelial cells, and infiltrating immune cells result in increased vascular permeability, cancer cell transmigration, and angiogenesis. Therefore antiangiogenic therapies such as Bevacizumab, a monoclonal antibody targeting VEGF-A, may have a potential role in the management of malignant pleural effusions. Herein we review the pathogenesis and potential treatment strategies of malignant pleural effusions, with a focus on angiogenesis and antiangiogenic therapeutics.

Haas AR, Sterman DH, Musani AI. Malignant pleural effusions: management options with consideration of coding, billing, and a decision approach. Chest. 2007;132(3):1036–41. doi:10.1378/chest.06-1757.PubMedCrossRef

Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc. 2008;83(2):235–50. doi:10.4065/83.2.235.PubMed

Anderson CB, Philpott GW, Ferguson TB. The treatment of malignant pleural effusions. Cancer. 1974;33(4):916–22.PubMedCrossRef

Memon A, Zawadzki ZA. Malignant effusions: diagnostic evaluation and therapeutic strategy. Curr Probl Cancer. 1981;5(8):1–30.PubMedCrossRef

Morgensztern D, Waqar S, Subramanian J, Trinkaus K, Govindan R. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer. J Thorac Oncol. 2012;7(10):1485–9. doi:10.1097/JTO.0b013e318267223a.PubMedCrossRef

Antunes G, Neville E, Duffy J, Ali N. BTS guidelines for the management of malignant pleural effusions. Thorax. 2003;58 Suppl 2:ii29–38.PubMed

Ide AG, Baker NH, Warren SL. Vascularization of the Brown Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am J Roentgenol. 1939;42:891–9.

Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–6. doi:10.1056/NEJM197111182852108.PubMedCrossRef

Hamed EA, El-Noweihi AM, Mohamed AZ, Mahmoud A. Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusions. Respirology. 2004;9(1):81–6. doi:10.1111/j.1440-1843.2003.00529.x.PubMedCrossRef

10.

Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005;65(3):671–80.PubMed

11.

Numnum TM, Rocconi RP, Whitworth J, Barnes MN. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol. 2006;102(3):425–8. doi:10.1016/j.ygyno.2006.05.018.PubMedCrossRef

12.

Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol. 2001;280(6):C1375–86.PubMed

13.

Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219(4587):983–5.PubMedCrossRef

14.

Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161(2):851–8.PubMedCrossRef

15.

Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–76. doi:10.1038/nm0603-669.PubMedCrossRef

16.

Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–27. doi:10.1200/JCO.2005.06.081.PubMedCrossRef

17.

Ku DD, Zaleski JK, Liu S, Brock TA. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol. 1993;265(2 Pt 2):H586–92.PubMed

18.

Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS. 1997;79:233–69.PubMed

19.

Mohammed KA, Nasreen N, Hardwick J, Logie CS, Patterson CE, Antony VB. Bacterial induction of pleural mesothelial monolayer barrier dysfunction. Am J Physiol Lung Cell Mol Physiol. 2001;281(1):L119–25.PubMed

20.

Bates DO. Vascular endothelial growth factors and vascular permeability. Cardiovasc Res. 2010;87(2):262–71. doi:10.1093/cvr/cvq105.PubMedCrossRef

21.

Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci. 1995;108(Pt 6):2369–79.PubMed

22.

Roberts WG, Palade GE. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res. 1997;57(4):765–72.PubMed

23.

Satchell SC, Braet F. Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier. Am J Physiol Renal Physiol. 2009;296(5):F947–56. doi:10.1152/ajprenal.90601.2008.PubMedCrossRef

24.

Michel CC, Neal CR. Openings through endothelial cells associated with increased microvascular permeability. Microcirculation. 1999;6(1):45–54.PubMed

25.

Feng D, Nagy JA, Hipp J, Pyne K, Dvorak HF, Dvorak AM. Reinterpretation of endothelial cell gaps induced by vasoactive mediators in guinea-pig, mouse and rat: many are transcellular pores. J Physiol. 1997;504(Pt 3):747–61.PubMedCrossRef

26.

Fujimoto K, Hosotani R, Wada M, Lee JU, Koshiba T, Miyamoto Y, et al. Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. Eur J Cancer. 1998;34(9):1439–47.PubMedCrossRef

27.

Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer. 1999;79(9–10):1553–63. doi:10.1038/sj.bjc.6690248.PubMedCrossRef

28.

Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996;77(5):858–63.PubMedCrossRef

29.

Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD, Ellis LM. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res. 1996;2(10):1679–84.PubMed

30.

Lee JC, Chow NH, Wang ST, Huang SM. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer. 2000;36(6):748–53.PubMedCrossRef

31.

Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995;55(18):3964–8.PubMed

32.

Fontanini G, Lucchi M, Vignati S, et al. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst. 1997;89:881–6.PubMedCrossRef

33.

Berns EM, Klijn JG, Look MP, Grebenchtchikov N, Vossen R, Peters H, et al. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. Clin Cancer Res. 2003;9(4):1253–8.PubMed

34.

Manders P, Beex LV, Tjan-Heijnen VC, Geurts-Moespot J, Van Tienoven TH, Foekens JA, et al. The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br J Cancer. 2002;87(7):772–8. doi:10.1038/sj.bjc.6600555.PubMedCrossRef

35.

George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res. 2001;7(7):1932–6.PubMed

36.

Gorski DH, Leal AD, Goydos JS. Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression. J Am Coll Surg. 2003;197(3):408–18. doi:10.1016/S1072-7515(03)00388-0.PubMedCrossRef

37.

Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581–611. doi:10.1210/er.2003-0027.PubMedCrossRef

38.

Voelkel NF, Vandivier RW, Tuder RM. Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol. 2006;290(2):L209–21. doi:10.1152/ajplung.00185.2005.PubMedCrossRef

39.

Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 1995;270(3):1230–7.PubMedCrossRef

40.

Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721–32. doi:10.1038/nrc1187.PubMedCrossRef

41.

Mayerhofer M, Valent P, Sperr WR, Griffin JD, Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood. 2002;100(10):3767–75. doi:10.1182/blood-2002-01-0109.PubMedCrossRef

42.

Mayerhofer M, Aichberger KJ, Florian S, Krauth MT, Hauswirth AW, Derdak S, et al. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB J. 2005;19(8):960–2. doi:10.1096/fj.04-1973fje.PubMed

43.

• Prager GW, Lackner EM, Krauth MT, Unseld M, Poettler M, Laffer S, et al. Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab. Mol Oncol. 2010;4(2):150–60. doi:10.1016/j.molonc.2010.01.002. VEGF induces endothelial permeability and tumor cell transmigration in vitro, effects which are mitigated by rapamycin or bevacizumab.PubMedCrossRef

44.

Yeh HH, Lai WW, Chen HH, Liu HS, Su WC. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene. 2006;25(31):4300–9. doi:10.1038/sj.onc.1209464.PubMedCrossRef

45.

Pritchard-Jones RO, Dunn DB, Qiu Y, Varey AH, Orlando A, Rigby H, et al. Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma. Br J Cancer. 2007;97(2):223–30. doi:10.1038/sj.bjc.6603839.PubMedCrossRef

46.

Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 2001;114(Pt 5):853–65.PubMed

47.

Soker S, Fidder H, Neufeld G, Klagsbrun M. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J Biol Chem. 1996;271(10):5761–7.PubMedCrossRef

48.

Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998;92(6):735–45.PubMedCrossRef

49.

Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20(21):4368–80.PubMedCrossRef

50.

Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W, et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 1993;72(6):835–46.PubMedCrossRef

51.

Zeng H, Dvorak HF, Mukhopadhyay D. Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem. 2001;276(29):26969–79. doi:10.1074/jbc.M103213200.PubMedCrossRef

52.

Grove CS, Lee YC. Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med. 2002;8(4):294–301.PubMedCrossRef

53.

Cheng D, Lee YC, Rogers JT, Perkett EA, Moyers JP, Rodriguez RM, et al. Vascular endothelial growth factor level correlates with transforming growth factor-beta isoform levels in pleural effusions. Chest. 2000;118(6):1747–53.PubMedCrossRef

54.

Croghan GA, Nichols F, Cassivi S, et al. VEGF A, C, and D levels in malignant pleural effusions. J Clin Oncol. 2008;26(15S):abst. 22126.

55.

Fiorelli A, Vicidomini G, Di Domenico M, Napolitano F, Messina G, Morgillo F, et al. Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. Interact Cardiovasc Thorac Surg. 2011;12(3):420–4. doi:10.1510/icvts.2010.250357.PubMedCrossRef

56.

Lieser E, Bradshaw M, Croghan G, Mullon J, Shen KR, Nichols F. Proangiogenesis factors and cell phenotyping in the etiology and diagnosis of malignant pleural effusions. J Thorac Oncol. 2011;6(6):S750–1.

57.

Sack U, Hoffmann M, Zhao XJ, Chan KS, Hui DS, Gosse H, et al. Vascular endothelial growth factor in pleural effusions of different origin. Eur Respir J. 2005;25(4):600–4. doi:10.1183/09031936.05.00037004.PubMedCrossRef

58.

Thickett DR, Armstrong L, Millar AB. Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax. 1999;54(8):707–10.PubMedCrossRef

59.

Yanagawa H, Takeuchi E, Suzuki Y, Ohmoto Y, Bando H, Sone S. Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol Immunother. 1999;48(7):396–400.PubMedCrossRef

60.

Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol. 1999;6(4):373–8.PubMedCrossRef

61.

Zebrowski BK, Yano S, Liu W, Shaheen RM, Hicklin DJ, Putnam Jr JB, et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res. 1999;5(11):3364–8.PubMed

62.

Ishii H, Yazawa T, Sato H, Suzuki T, Ikeda M, Hayashi Y, et al. Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs). Lung Cancer. 2004;45(3):325–37. doi:10.1016/j.lungcan.2004.02.021.PubMedCrossRef

63.

Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol. 2000;157(6):1893–903. doi:10.1016/S0002-9440(10)64828-6.PubMedCrossRef

64.

Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983–8. doi:10.1073/pnas.0530291100.PubMedCrossRef

65.

Cui R, Takahashi F, Ohashi R, Yoshioka M, Gu T, Tajima K, et al. Osteopontin is involved in the formation of malignant pleural effusion in lung cancer. Lung Cancer. 2009;63(3):368–74. doi:10.1016/j.lungcan.2008.06.020.PubMedCrossRef

66.

Stathopoulos GT, Psallidas I, Moustaki A, Moschos C, Kollintza A, Karabela S, et al. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J Natl Cancer Inst. 2008;100(20):1464–76. doi:10.1093/jnci/djn325.PubMedCrossRef

67.

Stathopoulos GT, Sherrill TP, Karabela SP, Goleniewska K, Kalomenidis I, Roussos C, et al. Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion. Am J Respir Crit Care Med. 2010;182(10):1273–81. doi:10.1164/rccm.201001-0001OC.PubMedCrossRef

68.

Stathopoulos GT, Kollintza A, Moschos C, Psallidas I, Sherrill TP, Pitsinos EN, et al. Tumor necrosis factor-alpha promotes malignant pleural effusion. Cancer Res. 2007;67(20):9825–34. doi:10.1158/0008-5472.CAN-07-1064.PubMedCrossRef

69.

•• Stathopoulos GT, Kalomenidis I. Malignant pleural effusion: tumor-host interactions unleashed. Am J Respir Crit Care Med. 2012;186(6):487–92. doi:10.1164/rccm.201203-0465PP. Presents a model of malignant pleural effusion pathogenesis integrating the interactions between tumor and host.PubMedCrossRef

70.

Korpanty G, Smyth E, Sullivan LA, Brekken RA, Carney DN. Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. Exp Biol Med (Maywood). 2010;235(1):3–9. doi:10.1258/ebm.2009.009191.CrossRef

71.

Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438(7070):967–74. doi:10.1038/nature04483.PubMedCrossRef

72.

Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335–45. doi:10.1007/s10456-004-8272-2.PubMedCrossRef

73.

Mitchell EP. Targeted therapy for metastatic colorectal cancer: role of aflibercept. Clin Colorectal Cancer. 2012. doi:10.1016/j.clcc.2012.08.001.PubMed

74.

Gordon MS, Margolin K, Talpaz M, Sledge Jr GW, Holmgren E, Benjamin R, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19(3):843–50.PubMed

75.

Karp JE, Gojo I, Pili R, Gocke CD, Greer J, Guo C, et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res. 2004;10(11):3577–85. doi:10.1158/1078-0432.CCR-03-0627.PubMedCrossRef

76.

Kazazi-Hyseni F, Beijnen JH, Schellens JH. Bevacizumab. Oncologist. 2010;15(8):819–25. doi:10.1634/theoncologist.2009-0317.PubMedCrossRef

77.

Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999;85(1):178–87.PubMedCrossRef

78.

Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001;193(4):468–75. doi:10.1002/path.824.PubMedCrossRef

79.

Yeo KT, Wang HH, Nagy JA, Sioussat TM, Ledbetter SR, Hoogewerf AJ, et al. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res. 1993;53(12):2912–8.PubMed

80.

Caine GJ, Lip GY, Blann AD. Platelet-derived VEGF, Flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer: further evidence for a role of platelets in tumour angiogenesis. Ann Med. 2004;36(4):273–7.PubMedCrossRef

81.

Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. 2000;60(22):6253–8.PubMed

82.

Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, et al. Tumor induction of VEGF promoter activity in stromal cells. Cell. 1998;94(6):715–25.PubMedCrossRef

83.

Tsuzuki Y, Fukumura D, Oosthuyse B, Koike C, Carmeliet P, Jain RK. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha–> hypoxia response element–> VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res. 2000;60(22):6248–52.PubMed

84.

Kishimoto J, Ehama R, Ge Y, Kobayashi T, Nishiyama T, Detmar M, et al. In vivo detection of human vascular endothelial growth factor promoter activity in transgenic mouse skin. Am J Pathol. 2000;157(1):103–10. doi:10.1016/S0002-9440(10)64522-1.PubMedCrossRef

85.

Gary Lee YC, Melkerneker D, Thompson PJ, Light RW, Lane KB. Transforming growth factor beta induces vascular endothelial growth factor elaboration from pleural mesothelial cells in vivo and in vitro. Am J Respir Crit Care Med. 2002;165(1):88–94.PubMedCrossRef

86.

Edge SB, American Joint Committee on Cancer. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.

87.

Heffner JE. Diagnosis and management of malignant pleural effusions. Respirology. 2008;13(1):5–20. doi:10.1111/j.1440-1843.2007.01154.x.PubMed

88.

Ryu JS, Ryu ST, Kim YS, Cho JH, Lee HL. What is the clinical significance of transudative malignant pleural effusion? Korean J Intern Med. 2003;18(4):230–3.PubMed

89.

Porcel JM, Alvarez M, Salud A, Vives M. Should a cytologic study be ordered in transudative pleural effusions? Chest. 1999;116(6):1836–7.PubMedCrossRef

90.

Light RW, Macgregor MI, Luchsinger PC, Ball Jr WC. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med. 1972;77(4):507–13.PubMedCrossRef

91.

Prakash UBS, Reiman HM. Comparison of needle-biopsy with cytologic analysis for the evaluation of pleural effusion - analysis of 414 cases. Mayo Clin Proc. 1985;60(3):158–64.PubMedCrossRef

92.

Sahn SA. Malignant pleural effusions. Clin Chest Med. 1985;6(1):113–25.PubMed

93.

Escudero Bueno C, Garcia Clemente M, Cuesta Castro B, Molinos Martin L, Rodriguez Ramos S, Gonzalez Panizo A, et al. Cytologic and bacteriologic analysis of fluid and pleural biopsy specimens with Cope's needle. Study of 414 patients. Arch Intern Med. 1990;150(6):1190–4.PubMedCrossRef

94.

Abouzgheib W, Bartter T, Dagher H, Pratter M, Klump W. A prospective study of the volume of pleural fluid required for accurate diagnosis of malignant pleural effusion. Chest. 2009;135(4):999–1001. doi:10.1378/chest.08-2002.PubMedCrossRef

95.

Sallach SM, Sallach JA, Vasquez E, Schultz L, Kvale P. Volume of pleural fluid required for diagnosis of pleural malignancy. Chest. 2002;122(6):1913–7.PubMedCrossRef

96.

Domej W, Tilz GP, Foldes-Papp Z, Demel U, Rabold T, Holzer H. Cystatin C of pleural effusion as a novel diagnostic aid in pleural diseases of different aetiologies. Clin Sci (Lond). 2002;102(3):373–80.CrossRef

97.

Matveychuk A, Rashid G, Fridman Z, Guber A, Shitrit D. Pleural ELFA D-dimer assay: a surrogate marker for malignant pleural effusion. Thromb Res. 2012;129(5):648–51. doi:10.1016/j.thromres.2011.07.036.PubMedCrossRef

98.

Pernemalm M, De Petris L, Eriksson H, Branden E, Koyi H, Kanter L, et al. Use of narrow-range peptide IEF to improve detection of lung adenocarcinoma markers in plasma and pleural effusion. Proteomics. 2009;9(13):3414–24. doi:10.1002/pmic.200800814.PubMedCrossRef

99.

Shijubo N, Honda Y, Fujishima T, Takahashi H, Kodama T, Kuroki Y, et al. Lung surfactant protein-A and carcinoembryonic antigen in pleural effusions due to lung adenocarcinoma and malignant mesothelioma. Eur Respir J. 1995;8(3):403–6.PubMedCrossRef

100.

Bard MP, Hegmans JP, Hemmes A, Luider TM, Willemsen R, Severijnen LA, et al. Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am J Respir Cell Mol Biol. 2004;31(1):114–21. doi:10.1165/rcmb.2003-0238OC.PubMedCrossRef

101.

Hsieh WY, Chen MW, Ho HT, You TM, Lu YT. Identification of differentially expressed proteins in human malignant pleural effusions. Eur Respir J. 2006;28(6):1178–85. doi:10.1183/09031936.06.00135405.PubMedCrossRef

102.

Rodriguez-Pineiro AM, Blanco-Prieto S, Sanchez-Otero N, Rodriguez-Berrocal FJ, de la Cadena MP. On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion. J Proteomics. 2010;73(8):1511–22. doi:10.1016/j.jprot.2010.03.005.PubMedCrossRef

103.

Botana-Rial M, Casado-Rey P, Leiro-Fernandez V, Andrade-Olivie M, Represas-Represas C, Fernandez-Villar A. Validity of procalcitonin and C-reactive protein measurement when differentiating between benign and malignant pleural effusion. Clin Lab. 2011;57(5–6):373–8.PubMed

104.

Cheng D, Rodriguez RM, Perkett EA, Rogers J, Bienvenu G, Lappalainen U, et al. Vascular endothelial growth factor in pleural fluid. Chest. 1999;116(3):760–5.PubMedCrossRef

105.

Yu CJ, Wang CL, Wang CI, Chen CD, Dan YM, Wu CC, et al. Comprehensive proteome analysis of malignant pleural effusion for lung cancer biomarker discovery by using multidimensional protein identification technology. J Proteome Res. 2011;10(10):4671–82. doi:10.1021/pr2004743.PubMedCrossRef

106.

Shen YC, Liu MQ, Wan C, Chen L, Wang T, Wen FQ. Diagnostic accuracy of vascular endothelial growth factor for malignant pleural effusion: a meta-analysis. Exp Ther Med. 2012;3(6):1072–6. doi:10.3892/etm.2012.514.PubMed

107.

Bielsa S, Martin-Juan J, Porcel JM, Rodriguez-Panadero F. Diagnostic and prognostic implications of pleural adhesions in malignant effusions. J Thorac Oncol. 2008;3(11):1251–6. doi:10.1097/JTO.0b013e318189f53d.PubMedCrossRef

108.

Bernard A, de Dompsure RB, Hagry O, Favre JP. Early and late mortality after pleurodesis for malignant pleural effusion. Ann Thorac Surg. 2002;74(1):213–7.PubMedCrossRef

109.

Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest. 2000;117(1):73–8.PubMedCrossRef

110.

Dresler CM, Olak J, Herndon 2nd JE, Richards WG, Scalzetti E, Fleishman SB, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest. 2005;127(3):909–15. doi:10.1378/chest.127.3.909.PubMedCrossRef

111.

Schulze M, Boehle AS, Kurdow R, Dohrmann P, Henne-Bruns D. Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients. Ann Thorac Surg. 2001;71(6):1809–12.PubMedCrossRef

112.

Rodriguez-Panadero F, Lopez-Mejias J. Survival time of patients with pleural metastatic carcinoma predicted by glucose and pH studies. Chest. 1989;95(2):320–4.PubMedCrossRef

113.

Sahn SA, Good Jr JT. Pleural fluid pH in malignant effusions. Diagnostic, prognostic, and therapeutic implications. Ann Intern Med. 1988;108(3):345–9.PubMedCrossRef

114.

Sanchez-Armengol A, Rodriguez-Panadero F. Survival and talc pleurodesis in metastatic pleural carcinoma, revisited. Report of 125 cases. Chest. 1993;104(5):1482–5.PubMedCrossRef

115.

Love D, White D, Kiroff G. Thoracoscopic talc pleurodesis for malignant pleural effusion. ANZ J Surg. 2003;73(1–2):19–22.PubMed

116.

Viallat JR, Rey F, Astoul P, Boutin C. Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases. Chest. 1996;110(6):1387–93.PubMedCrossRef

117.

Hirayama N, Tabata C, Tabata R, Maeda R, Yasumitsu A, Yamada S, et al. Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma. Respir Med. 2011;105(1):137–42. doi:10.1016/j.rmed.2010.10.010.PubMedCrossRef

118.

Davies HE, Steer H, Fysh E, et al. Diagnosis and management of malignant pleural effusions. Minerva Pneumonol. 2010;49:237–52.

119.

Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev. 2004;1:CD002916. doi:10.1002/14651858.CD002916.pub2.PubMed

120.

Burgers JA, Kunst PW, Koolen MG, Willems LN, Burgers JS, van den Heuvel M. Pleural drainage and pleurodesis: implementation of guidelines in four hospitals. Eur Respir J. 2008;32(5):1321–7. doi:10.1183/09031936.00165607.PubMedCrossRef

121.

Demmy TL, Gu L, Burkhalter JE, Toloza EM, D'Amico TA, Sutherland S, et al. Optimal management of malignant pleural effusions (results of CALGB 30102). J Natl Compr Canc Netw. 2012;10(8):975–82.PubMed

122.

Olden AM, Holloway R. Treatment of malignant pleural effusion: PleuRx catheter or talc pleurodesis? A cost-effectiveness analysis. J Palliat Med. 2010;13(1):59–65. doi:10.1089/jpm.2009.0220.PubMedCrossRef

123.

Suzuki K, Servais EL, Rizk NP, Solomon SB, Sima CS, Park BJ, et al. Palliation and pleurodesis in malignant pleural effusion: the role for tunneled pleural catheters. J Thorac Oncol. 2011;6(4):762–7. doi:10.1097/JTO.0b013e31820d614f.PubMedCrossRef

124.

Van Meter ME, McKee KY, Kohlwes RJ. Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review. J Gen Intern Med. 2011;26(1):70–6. doi:10.1007/s11606-010-1472-0.PubMedCrossRef

125.

Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest. 2006;129(2):362–8. doi:10.1378/chest.129.2.362.PubMedCrossRef

126.

Bogliolo GV, Lerza R, Bottino GB, Mencoboni MP, Pannacciulli IM, Vannozzi M, et al. Regional pharmacokinetic selectivity of intrapleural cisplatin. Eur J Cancer. 1991;27(7):839–42.PubMedCrossRef

127.

Figlin R, Mendoza E, Piantadosi S, Rusch V. Intrapleural chemotherapy without pleurodesis for malignant pleural effusions. LCSG Trial 861. Chest. 1994;106(6 Suppl):363S–6S.PubMed

128.

Jones DR, Taylor MD, Petroni GR, Shu J, Burks SG, Daniel TM, et al. Phase I trial of intrapleural docetaxel administered through an implantable catheter in subjects with a malignant pleural effusion. J Thorac Oncol. 2010;5(1):75–81. doi:10.1097/JTO.0b013e3181c07ddc.PubMedCrossRef

129.

Lerza R, Vannozzi MO, Tolino G, Viale M, Bottino GB, Bogliolo G, et al. Carboplatin and cisplatin pharmacokinetics after intrapleural combination treatment in patients with malignant pleural effusion. Ann Oncol. 1997;8(4):385–91.PubMedCrossRef

130.

Masuno T, Kishimoto S, Ogura T, Honma T, Niitani H, Fukuoka M, et al. A comparative trial of LC9018 plus doxorubicin and doxorubicin alone for the treatment of malignant pleural effusion secondary to lung cancer. Cancer. 1991;68(7):1495–500.PubMedCrossRef

131.

Muraoka M, Oka T, Akamine S, Tagawa T, Morinaga M, Inoue M, et al. Modified intrapleural cisplatin treatment for lung cancer with positive pleural lavage cytology or malignant effusion. J Surg Oncol. 2006;93(4):323–9. doi:10.1002/jso.20470.PubMedCrossRef

132.

Perng RP, Wu MF, Lin SY, Chen YM, Lin JY, Whang-Peng J. A phase I feasibility and pharmacokinetic study of intrapleural paclitaxel in patients with malignant pleural effusions. Anticancer Drugs. 1997;8(6):565–73.PubMedCrossRef

133.

Shoji T, Tanaka F, Yanagihara K, Inui K, Wada H. Phase II study of repeated intrapleural chemotherapy using implantable access system for management of malignant pleural effusion. Chest. 2002;121(3):821–4.PubMedCrossRef

134.

Tohda Y, Iwanaga T, Takada M, Yana T, Kawahara M, Negoro S, et al. Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer. Chemotherapy. 1999;45(3):197–204.PubMedCrossRef

135.

Wang X, Zhou J, Wang Y, Zhu Z, Lu Y, Wei Y, et al. A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. Eur J Cancer. 2010;46(8):1474–80. doi:10.1016/j.ejca.2010.02.002.PubMedCrossRef

136.

Yoshida K, Sugiura T, Takifuji N, Kawahara M, Matsui K, Kudoh S, et al. Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515. Lung Cancer. 2007;58(3):362–8. doi:10.1016/j.lungcan.2007.07.009.PubMedCrossRef

137.

Sterman DH, Recio A, Haas AR, Vachani A, Katz SI, Gillespie CT, et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther. 2010;18(4):852–60. doi:10.1038/mt.2009.309.PubMedCrossRef

138.

Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A, et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res. 2007;13(15 Pt 1):4456–66. doi:10.1158/1078-0432.CCR-07-0403.PubMedCrossRef

139.

Ren S, Terman DS, Bohach G, Silvers A, Hansen C, Colt H, et al. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer. Chest. 2004;126(5):1529–39. doi:10.1378/chest.126.5.1529.PubMedCrossRef

140.

Ribeiro SC, Vargas FS, Antonangelo L, Marchi E, Genofre EH, Acencio MM, et al. Monoclonal anti-vascular endothelial growth factor antibody reduces fluid volume in an experimental model of inflammatory pleural effusion. Respirology. 2009;14(8):1188–93. doi:10.1111/j.1440-1843.2009.01628.x.PubMedCrossRef

141.

Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB. Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol. 2002;161(5):1917–24. doi:10.1016/S0002-9440(10)64467-7.PubMedCrossRef

142.

Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol. 1998;153(4):1249–56. doi:10.1016/S0002-9440(10)65669-6.PubMedCrossRef

143.

Gossmann A, Helbich TH, Mesiano S, Shames DM, Wendland MF, Roberts TP, et al. Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor. Am J Obstet Gynecol. 2000;183(4):956–63. doi:10.1067/mob.2000.107092.PubMedCrossRef

144.

Luo JC, Toyoda M, Shibuya M. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res. 1998;58(12):2594–600.PubMed

145.

Shaheen RM, Ahmad SA, Liu W, Reinmuth N, Jung YD, Tseng WW, et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer. 2001;85(4):584–9. doi:10.1054/bjoc.2001.1936.PubMedCrossRef

146.

Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res. 2000;6(3):957–65.PubMed

147.

Watanabe M, Boyer JL, Crystal RG. AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors. Gene Ther. 2010;17(8):1042–51.PubMedCrossRef

148.

Shibuya M, Luo JC, Toyoda M, Yamaguchi S. Involvement of VEGF and its receptors in ascites tumor formation. Cancer Chemother Pharmacol. 1999;43(Suppl):S72–7.PubMedCrossRef

149.

Teixeira LR, Vargas FS, Acencio MM, Ribeiro SC, Sales RK, Antonangelo L, et al. Blockage of vascular endothelial growth factor (VEGF) reduces experimental pleurodesis. Lung Cancer. 2011. doi:10.1016/j.lungcan.2011.04.015.PubMed

150.

Guo YB, Kalomenidis I, Hawthorne M, Parman KS, Lane KB, Light RW. Pleurodesis is inhibited by anti-vascular endothelial growth factor antibody. Chest. 2005;128(3):1790–7. doi:10.1378/chest.128.3.1790.PubMedCrossRef

151.

Pichelmayer O, Zielinski C, Raderer M. Response of a nonmalignant pleural effusion to bevacizumab. N Engl J Med. 2005;353(7):740–1. doi:10.1056/NEJM200508183530721.PubMedCrossRef

152.

Bae SH, Hwang JY, Kim WJ, Yoon HH, Kim JM, Nam YH, et al. A case of cardiac amyloidosis with diuretic-refractory pleural effusions treated with bevacizumab. Korean Circ J. 2010;40(12):671–6. doi:10.4070/kcj.2010.40.12.671.PubMedCrossRef

153.

Pichelmayer O, Gruenberger B, Zielinski C, Raderer M. Bevacizumab is active in malignant effusion. Ann Oncol. 2006;17(12):1853. doi:10.1093/annonc/mdl143.PubMedCrossRef

154.

Kitamura K, Kubota K, Ando M, Takahashi S, Nishijima N, Sugano T, et al. Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion. Cancer Chemother Pharmacol. 2013;71(2):457–61. doi:10.1007/s00280-012-2026-4.PubMedCrossRef

155.

Kesterson JP, Mhawech-Fauceglia P, Lele S. The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report. Gynecol Oncol. 2008;111(3):527–9. doi:10.1016/j.ygyno.2008.07.015.PubMedCrossRef

156.

Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Farley JH, Rose GS. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol. 2008;111(3):530–2. doi:10.1016/j.ygyno.2008.04.028.PubMedCrossRef

157.

El-Shami K, Elsaid A, El-Kerm Y. Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites. J Clin Oncol. 2007;25(18 Suppl):9043.

Titel: The Role of Vascular Endothelial Growth Factor in the Pathogenesis, Diagnosis and Treatment of Malignant Pleural Effusion
verfasst von: Michael Bradshaw
Aaron Mansfield
Tobias Peikert
Publikationsdatum: 01.06.2013
Verlag: Current Science Inc.
Erschienen in: Current Oncology Reports / Ausgabe 3/2013
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-013-0315-7

Springer Medizin

The Role of Vascular Endothelial Growth Factor in the Pathogenesis, Diagnosis and Treatment of Malignant Pleural Effusion

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2013

Novel Immunotherapies in GU Malignancies

Transplantation for Refractory Germ Cell Tumors: Does it Really Make a Difference?

Does Pharmacogenomics Account for Variability in Control of Acute Chemotherapy-Induced Nausea and Vomiting with 5-Hydroxytryptamine Type 3 Receptor Antagonists?

Provider Impact on Survival Outcomes in the Management of Malignant Disease

Follow-Up of Epithelial Ovarian Cancer: Overdue For A Major Rethink

Secondary Cytoreduction Versus Chemotherapy Alone in the Treatment of Patients with Recurrent Ovarian Cancer: Is a Randomized Trial Worthwhile?

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie